Gilead and Gala­pa­gos bag promis­ing PhII da­ta for star im­munol­o­gy drug fil­go­tinib — boost­ing late-stage fo­cus

Gilead $GILD and its part­ners at Gala­pa­gos $GLPG picked up some “very im­pres­sive” mid-stage da­ta for their star im­munol­o­gy drug fil­go­tinib, which hand­i­ly beat out a place­bo in treat­ing pso­ri­at­ic arthri­tis. 

Deep in­to a Phase III pro­gram for rheuma­toid arthri­tis, re­searchers say that the drug col­lect­ed an ACR20 score of 80% ver­sus 33% for the sug­ar pill, hit­ting the pri­ma­ry end­point. Com­pare that to Pfiz­er’s Xel­janz, which was ap­proved for this con­di­tion with an ACR20 of 50%. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER